Loading...
ADAP ADAPTIMMUNE THERAPEUTICS PLC US FDA Inspections 8-K Filing
Back
DPTM
DP
ADAPTIMMUNE THERAPEUTICS PLC
(ADAP)
Follow
FY2023 8 K
View More
Back
DPTM
DP
ADAPTIMMUNE THERAPEUTICS PLC
(ADAP)
Follow
FY2023 8 K
Filing:
8 K
Published on:
6 Dec '23
Transfer of Listing
1 May '25
Management Change
14 Apr '25
Loan Agreement Amendment
24 Mar '25
Financial Update
20 Mar '25
Management Changes
19 Dec '24
Workforce Reduction
13 Nov '24
Trial Data Announcement
13 Nov '24
Nasdaq Compliance
1 Nov '24
Collaboration Termination
23 Sep '24
Q2 Financial Results
12 Aug '24
FDA Approval of TECELRA
2 Aug '24
Amended Severance Policy
16 Jul '24
Executive Severance Policy
11 Jun '24
Clinical Collaboration Agre...
30 May '24
Financial Results
15 May '24
Loan Agreement
15 May '24
Annual General Meeting
14 May '24
Termination of Agreement
12 Apr '24
Financial Results Announcement
6 Mar '24
Appointment of Chief Commer...
27 Feb '24
Delisting
16 Feb '24
FDA Accepts Adaptimmune's B...
31 Jan '24
Adaptimmune Therapeutics Pl...
4 Jan '24
Submission of Biologics Lic...
6 Dec '23
Amendment to Annual Report
14 Nov '23
Financial Results Announcement
8 Nov '23
Resignation of Director
3 Nov '23
Press Release
31 Oct '23
Delisting Notice
31 Aug '23
Financial Results Announcement
9 Aug '23
Amendments to Share Option ...
29 Jun '23
Completion of Merger
1 Jun '23
Shareholder Meeting Approval
30 May '23
Merger Agreement
22 May '23
Annual General Meeting
16 May '23
Financial Results and Corpo...
12 May '23
Termination and Transfer Ag...
11 Apr '23
Regulatory Disclosure
10 Mar '23
Termination, Financial Resu...
6 Mar '23
Merger Agreement
6 Mar '23
Appointment and Resignation
16 Feb '23
Termination of Material Def...
31 Jan '23
External Links:
SEC
AI Assistant
Close
ADAPTIMMUNE THERAPEUTICS PLC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.